IGLVI-63

Across TCGA pan-cancer cohorts, IGLVI-63 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of IGLVI-63’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where IGLVI-63 RNA is repressed in tumor relative to normal tissue. In most cancer types IGLVI-63 is over-expressed in tumor, although a few such as COAD and STAD show the opposite, repressed pattern.

COAD, STAD, and BRCA are the cancer types where IGLVI-63 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLVI-63 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	III,IV	−0.856	<.001	7	view →
STAD	Male	IV	−1.615	.001	5	view →
BRCA	Female	II,III,IV	−0.117	.004	4	view →
LUAD	All	All	+0.228	.001	3	view →
ESCA	All	II,III,IV	+0.675	.019	2	view →
KIRP	Female	All	−0.071	.040	1	view →
KIRC	All	All	+0.060	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

IGLVI-63–COAD

Open the COAD breakdown →